UPPSALA, Sweden, Feb. 8, 2024 /PRNewswire/ — Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights Total net revenues of SEK 166.0 m (156.1) EBITDA of SEK 12.4 m (-53.1), EBITDA excluding costs for legal processes and external non-repeating clinical trials, SEK 23.4 m…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.